Published in Mol Cancer Ther on May 01, 2012
A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood (2013) 1.00
Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. J Thorac Oncol (2013) 0.82
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. Chem Biol (2015) 0.79
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Invest New Drugs (2014) 0.78
eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells. Cancer Res (2014) 0.78
Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. J Biol Chem (2016) 0.77
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. Cell Death Dis (2015) 0.77
Translational control of the fibroblast-extracellular matrix association: An application to pulmonary fibrosis. Translation (Austin) (2013) 0.75
Targeting translation initiation in breast cancer. Translation (Austin) (2014) 0.75
Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: A Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E. Sci Rep (2016) 0.75
Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget (2016) 0.75
Cancer genes and the pathways they control. Nat Med (2004) 24.22
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell (2009) 14.51
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Targeted cancer therapy. Nature (2004) 7.81
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature (1990) 7.74
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
eIF-4E expression and its role in malignancies and metastases. Oncogene (2004) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Translational control in cancer. Nat Rev Cancer (2010) 4.59
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
The experimental study of tumor progression: a review. Cancer Res (1954) 4.03
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J (1992) 3.66
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol (1999) 3.46
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
New approaches to molecular cancer therapeutics. Nat Chem Biol (2006) 2.28
Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell (2005) 2.17
Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res (2004) 2.06
Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem (1995) 1.90
How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog (1993) 1.73
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis (2006) 1.65
Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer (2008) 1.62
Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene (2004) 1.58
The role of Myc-induced protein synthesis in cancer. Cancer Res (2009) 1.54
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res (2011) 1.35
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res (2008) 1.35
Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res (2010) 1.31
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A (2010) 1.30
Translation of an uncapped mRNA involves scanning. J Biol Chem (1997) 1.27
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther (2008) 1.26
Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res (2007) 1.23
Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Mol Pharm (2007) 1.22
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther (2009) 1.21
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res (2011) 1.20
Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther (2010) 1.17
Functional genetics and experimental models of human cancer. Trends Mol Med (2004) 1.17
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia (2010) 1.16
Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res (2006) 1.10
Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res (2009) 1.09
The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol (2006) 1.09
Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res (2009) 1.06
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol (2008) 1.05
Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA (2004) 1.04
Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg (2002) 1.04
Targeting RAF: trials and tribulations. Nat Med (2011) 1.03
Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol (2009) 0.99
Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res (2010) 0.94
Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP. Eur J Med Chem (2009) 0.94
Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. Bioorg Med Chem Lett (2005) 0.93
The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling. Cancer Res (2010) 0.92
Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA (2005) 0.90
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res (2011) 0.88
The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA (2005) 0.88
Translational control and cancer therapy. Cell Cycle (2008) 0.84
Cell plasticity in lung injury and repair: report from an NHLBI workshop, April 19-20, 2010. Proc Am Thorac Soc (2011) 0.83
Antiviral nucleoside drug delivery via amino acid phosphoramidates. Nucleosides Nucleotides (1999) 0.83
Translational dysregulation by Pateamine A. Chem Biol (2007) 0.79
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol (2002) 1.42
Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem (2002) 1.35
Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res (2006) 1.27
Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res (2006) 1.10
Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res (2009) 1.06
Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol (2009) 0.99
Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem (2004) 0.96
Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. Bioorg Med Chem Lett (2005) 0.93
Translational control of cell fate: from integration of environmental signals to breaching anticancer defense. Cell Cycle (2012) 0.88
Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expr Purif (2008) 0.83